---
title: "PSMA PET/CT Plus mpMRI Improves Detection of Exclusionary Features for Prostate Cancer Focal Thera"
id: "medrxiv-19-prostate-specific-membrane-antigen-pet-ct-complements-mri-for-focal-therapy"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-prostate-specific-membrane-antigen-pet-ct-complements-mri-for-focal-therapy"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.09.26362553v1?rss=1"
published_at: "2026-09-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PSMA PET/CT Plus mpMRI Improves Detection of Exclusionary Features for Prostate Cancer Focal Thera
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-prostate-specific-membrane-antigen-pet-ct-complements-mri-for-focal-therapy
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.09.26362553v1?rss=1)
- **Published At:** 2026-09-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective whole-mount histopathology (WMHP) study evaluated whether **PSMA PET/CT**, **mpMRI**, or their combination correctly determine eligibility for prostate cancer **focal therapy** when validated against radical prostatectomy specimens. - Included were 112 patients (UCLA, 2017–2024) with preoperative PSMA PET/CT and mpMRI, biopsy grade group ≤3, unilateral disease, and PSA 3 focus at prostatectomy. - On WMHP, 77 of 112 patients (69%) were ineligible for focal therapy; 19 (17%) had a GG>3 focus at prostatectomy. - Per-modality sensitivity/specificity: PSMA PET/CT 53%/54%; mpMRI 70%/49%. - Combined imaging (PET+mpMRI) increased sensitivity to 83% (statistically significant vs PET and vs MRI) but reduced specificity to 26%. - At the observed prevalence, combined imaging would identify about 9 additional ineligible patients per 100 but falsely exclude about 7 true candidates per 100. - mpMRI was more sensitive than PET for detecting EPE (77% vs 32%, P<0.001); PET was more specific for EPE (90% vs 58%, P<0.001). - Combined imaging improved detection of multifocal disease (44% vs 23%, P=0.001) and bilateral disease (45% vs 23%, P=0.002) compared with mpMRI alone. - Conclusion: **PSMA PET/CT complements mpMRI** by improving sensitivity for exclusionary features, reflecting complementary molecular and anatomic information, but combined imaging still misses substantial adverse pathology and therefore imaging alone should not determine focal therapy eligibility.
## Clinical Analysis & Structured Key Points
Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study | medRxiv Skip to main content Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study View ORCID Profile Ida Sonni , Zahra Mohammadigoldar , George Furey , View ORCID Profile Koichiro Kimura , View ORCID Profile Pranav C. Movva , Adrien Holzgreve , Shadfar Bahri , Tyler Sevco , Alex Chung , Anthony Sisk , Tristan Grogan , Johannes Czernin , Kyunghyun Sung , View ORCID Profile Jeremie Calais , Scott E. Eggener , Wayne Brisbane , Robert E. Reiter , Steven Raman , View ORCID Profile Adam B. Weiner doi: https://doi.org/10.64898/2026.09.09.26362553 Ida Sonni 1 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ida Sonni Zahra Mohammadigoldar 1 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site George Furey 1 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Koichiro Kimura 2 Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Koichiro Kimura Pranav C. Movva 3 Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Pranav C. Movva Adrien Holzgreve 4 Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA; Department of Nuclear Medicine, LMU University Hospital, L; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shadfar Bahri 2 Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tyler Sevco 1 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alex Chung 1 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Anthony Sisk 5 Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tristan Grogan 6 Department of Medicine Statistics Core, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Johannes Czernin 2 Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kyunghyun Sung 1 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jeremie Calais 2 Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jeremie Calais Scott E. Eggener 7 Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Wayne Brisbane 7 Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Robert E. Reiter 7 Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Steven Raman 1 Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Adam B. Weiner 8 Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Adam B. Weiner For correspondence: adam.weiner{at}csmc.edu Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: The incremental value of PSMA PET/CT over multiparametric MRI (mpMRI) for selecting patients for prostate cancer focal therapy is undefined. Unlike lesion-detection studies, we evaluated whether PSMA PET/CT, mpMRI, and their combination correctly determine focal therapy eligibility when validated against whole-mount histopathology (WMHP). Methods: We retrospectively analyzed patients undergoing radical prostatectomy (RP) at UCLA (2017-2024) with preoperative PSMA PET/CT and mpMRI, biopsy grade group (GG) ≤3, unilateral disease, and prostate-specific antigen 3 focus at RP. Modalities were compared by McNemar tests. Results: Of 112 patients, 77 (69%) were ineligible on WMHP, including 19 (17%) with a GG>3 focus at RP. Sensitivity and specificity were 53% and 54% for PET and 70% and 49% for mpMRI. Combined imaging improved sensitivity to 83% (P<0.001 vs PET; P=0.002 vs MRI) but reduced specificity to 26%. Per 100 patients at this prevalence, this would correctly identify approximately 9 additional ineligible patients while falsely excluding approximately 7 true candidates. mpMRI was more sensitive than PET for EPE (77% vs 32%, P<0.001), whereas PET was more specific (90% vs 58%, P<0.001). Combined imaging improved detection of multifocal (44% vs 23%, P=0.001) and bilateral disease (45% vs 23%, P=0.002) versus MRI alone. Conclusions: Adding PSMA PET/CT to mpMRI significantly improves sensitivity for exclusionary features, reflecting complementary molecular and anatomic information. However, combined imaging still misses a substantial proportion of adverse pathology, so imaging alone should not determine eligibility. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board of the University of California, Los Angeles gave ethical approval for this work (10-1863). The need for written informed consent was waived given the retrospective design. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The datasets generated and analyzed during the current study are not publicly available owing to institutional privacy restrictions but are available from the corresponding author on reasonable request. Funder Information Declared Department of Defense Congressionally Directed Medical Research Programs , HT94252410589 Prostate Cancer Foundation , 23YOUN21 Simon-Strauss Foundation Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 11, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study Ida Sonni , Zahra Mohammadigoldar , George Furey , Koichiro Kimura , Pranav C. Movva , Adrien Holzgreve , Shadfar Bahri , Tyler Sevco , Alex Chung , Anthony Sisk , Tristan Grogan , Johannes Czernin , Kyunghyun Sung , Jeremie Calais , Scott E. Eggener , Wayne Brisbane , Robert E. Reiter , Steven Raman , Adam B. Weiner medRxiv 2026.09.09.26362553; doi: https://doi.org/10.64898/2026.09.09.26362553 Share This Article: Copy Citation Tools Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic Study Ida Sonni , Zahra Mohammadigoldar , George Furey , Koichiro Kimura , Pranav C. Movva , Adrien Holzgreve , Shadfar Bahri , Tyler Sevco , Alex Chung , Anthony Sisk , Tristan Grogan , Johannes Czernin , Kyunghyun Sung , Jeremie Calais , Scott E. Eggener , Wayne Brisbane , Robert E. Reiter , Steven Raman , Adam B. Weiner medRxiv 2026.09.09.26362553; doi: https://doi.org/10.64898/2026.09.09.26362553 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (898) Anesthesia (330) Cardiovascular Medicine (4802) Dentistry and Oral Medicine (478) Dermatology (414) Emergency Medicine (647) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1625) Epidemiology (15918) Forensic Medicine (32) Gastroenterology (1200) Genetic and Genomic Medicine (7033) Geriatric Medicine (732) Health Economics (1064) Health Informatics (5031) Health Policy (1432) Health Systems and Quality Improvement (1757) Hematology (584) HIV/AIDS (1343) Infectious Diseases (except HIV/AIDS) (16278) Intensive Care and Critical Care Medicine (1170) Medical Education (667) Medical Ethics (153) Nephrology (722) Neurology (7254) Nursing (366) Nutrition (1080) Obstetrics and Gynecology (1239) Occupational and Environmental Health (1004) Oncology (3599) Ophthalmology (1048) Orthopedics (397) Otolaryngology (451) Pain Medicine (469) Palliative Medicine (139) Pathology (706) Pediatrics (1794) Pharmacology and Therapeutics (736) Primary Care Research (764) Psychiatry and Clinical Psychology (5881) Public and Global Health (9739) Radiology and Imaging (2409) Rehabilitation Medicine and Physical Therapy (1448) Respiratory Medicine (1246) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (775) Toxicology (107) Transplantation (304) Urology (290)
## Related Clinical Research

- [Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi](https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies.md)
- [Hormonal Management in Older Transgender and Gender Diverse Adults: Case-Based Considerations](https://medichelpline.com/clinical-feed/pubmed-42274359.md) (DOI: 10.1210/clinem/dgag231)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)
- [Absolute Benefit of Androgen Deprivation Therapy Added to Radiotherapy for Localized Prostate Canc](https://medichelpline.com/clinical-feed/medrxiv-0-absolute-benefit-of-androgen-deprivation-therapy-with-radiotherapy-for.md)
- [Replacing animal fats with plant fats linked to lower mortality after nonmetastatic prostate cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-swapping-animal-fats-with-plant-fats-may-lower-risk-of-death-after-prostate.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.